ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS OF TREATING BLEPHARITIS Russian patent published in 2025 - IPC A61K9/08 A61K31/45 A61P27/02 A61P33/14 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to the pharmaceutical industry, specifically to the treatment of Demodex blepharitis in a human patient. Method of treating Demodex blepharitis in a human patient, comprising: local introduction directly on the ocular surface of one or more eyes of the patient in need of treatment, an effective amount of Lotilaner prepared in the ophthalmic composition, wherein said ophthalmic composition contains 0.25 wt.% of Lotilaner based on the total weight of said composition, wherein said ophthalmic composition is sterile, and wherein said Lotilaner is the only active ingredient of said ophthalmic composition. Method of treating Demodex blepharitis in a human patient, comprising: local administration directly to one or more of the eye, eyelids or eyelashes of a patient in need of treatment, an effective amount of Lotilaner prepared in an ophthalmic composition, wherein said ophthalmic composition contains 0.25 wt.% of Lotilaner based on the total weight of said composition, and said ophthalmic composition is sterile. Method of treating Demodex ocular invasion in a human patient, comprising: local administration directly to one or more eyes, eyelids or eyelashes of one or more eyes of a patient in need of treatment, an effective amount of Lotilaner prepared in an ophthalmic composition, wherein said ophthalmic composition contains 0.25 wt.% of Lotilaner based on the total weight of said composition, and said ophthalmic composition is sterile. Method of treating Demodex blepharitis in a human patient, comprising: topical application of Lotilaner, prepared as part of an ophthalmic composition, near one or more eyelashes, wherein said ophthalmic composition contains 0.25 wt.% of Lotilaner based on total weight of said composition, wherein said topical application is therapeutically effective for preferential absorption of Demodex mite body compared to ingestion by Demodex mite sufficient to cause a decrease in the movement of the body of the Demodex mite compared to the head of the Demodex mite, wherein said method is sufficient to reduce or eliminate Demodex mites near eyelashes, as a result of which there is relief of manifestations of blepharitis. Topical ophthalmic formulation for treating Demodex blepharitis in a human patient, comprising: effective amount of Lotilaner, prepared in ophthalmic composition, wherein said ophthalmic composition contains 0.25 wt.% of Lotilaner based on the total weight of said composition, wherein said ophthalmic composition is sterile, and wherein said Lotilaner is the only active ingredient of said ophthalmic formulation. Ophthalmic composition for treating Demodex blepharitis in a human patient, containing Lotilaner, wherein said ophthalmic composition is in the form of eye drops, wherein said ophthalmic composition is sterile, and Lotilaner is present in amount of 0.25 wt.% based on the total weight of said composition.

EFFECT: above-described group of inventions provides effective treatment of Demodex blepharitis in a human patient using a composition in the form of eye drops having high bioavailability.

19 cl, 4 dwg, 1 tbl